[Radioimmunotherapy is rapidly developing to clinically efficient therapy].
The use of monoclonal antibodies (mabs) in cancer therapy has gained renewed interest, due to recent reports of remarkable clinical response, particularly in patients with low-grade non-Hodgkin lymphoma. Better defined and more appropriate target antigens and "humanized" mabs, reducing the risk of inducing neutralising human anti-mouse antibodies, have contributed to the improvement in results. Conjugation of mabs with various radionuclides is now being explored as a means of further enhancing clinical efficacy, the idea being to allow systemic delivery of targeted radiation to areas of disease while sparing normal tissue. Radioimmunotherapy may be administered as a single large dose of radiolabelled mabs, usually requiring haematological stem cell support, or as multiple, smaller fractions. The criteria for the selection of mabs and radionuclides are discussed in the article, as are recent clinical data and the problems and prospects of future developments in radioimmunotherapy.
Stenke
L
L
Centrum för hematologi, medicindivisionen, Karolinska sjukhuset, Stockholm. leif.stenke@kids.ki.se
Lewensohn
R
R
Carlsson
J
J
D002986:Clinical Trials as Topic; D006801:Humans; D016499:Radioimmunotherapy / Q000379:methods / Q000592:standards / Q000639:trends